Limited Offer
Emerging Applications of Molecular Imaging to Oncology
- 1st Edition, Volume 124 - September 25, 2014
- Editors: Martin Pomper, Paul B. Fisher
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 4 1 1 6 3 8 - 2
- eBook ISBN:9 7 8 - 0 - 1 2 - 4 1 1 6 3 4 - 4
Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presen… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteAdvances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics. This volume, number 124, covers emerging applications of molecular imaging to oncology, including molecular-genetic imaging, imaging the tumor microenvironment, tracking cells and vaccines in vivo, and more.
- Provides information on cancer research
- Outstanding and original reviews
- Suitable for researchers and students
Researchers and students in the basic and clinical sciences of cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology, and molecular biology.
- Preface
- Chapter One: Quantitative Radiology: Applications to Oncology
- Abstract
- 1 Introduction
- 2 Radiological Characterization of Tumors
- 3 Quantitative Radiology
- 4 Future Directions
- 5 Conclusion
- Chapter Two: The Intricate Role of CXCR4 in Cancer
- Abstract
- 1 Introduction
- 2 CXCR4/CXCL12 Signaling
- 3 Expression and Physiological Functions of the CXCR4/CXCL12 Axis
- 4 Role of CXCR4 in Cancer
- 5 CXCR4 Antagonists as Therapeutic and Imaging Agents
- 6 Peptides and Peptidomimetics
- 7 Conclusion
- Acknowledgments
- Chapter Three: Recent Advances in Nanoparticle-Based Nuclear Imaging of Cancers
- Abstract
- 1 Introduction
- 2 Lipid-Based Nanoparticles
- 3 Dendrimers
- 4 Polymers
- 5 Quantum Dots
- 6 Iron Oxide Nanoparticles
- 7 Gold Nanoparticles
- 8 Carbon Nanotubes
- 9 Silica-Based Nanoparticles
- 10 Conclusion
- Chapter Four: Molecular-Genetic Imaging of Cancer
- Abstract
- 1 Introduction
- 2 Promoters
- 3 Reporters
- 4 Signal Enhancement of Reporters
- 5 Prolonged Expression of Reporters
- 6 Machinery for Gene Delivery
- 7 Size and Immunogenicity
- 8 Concluding Remarks
- Acknowledgments
- Chapter Five: Real-Time Fluorescence Image-Guided Oncologic Surgery
- Abstract
- 1 Introduction
- 2 Fluorescence Imaging Systems for Intraoperative Procedures
- 3 Current Intraoperative Optical Image Guidance Systems
- 4 Fluorescent Agents Used in Image-Guided Surgery
- 5 Clinical Applications of Fluorescence Image-Guided Surgery
- 6 Future Directions
- 7 Concluding Remarks
- Chapter Six: Cerenkov Imaging
- Abstract
- 1 Introduction
- 2 Cerenkov Radiation Physics (Simplified)
- 3 Application of Cerenkov in Biological Sciences: CLI
- 4 Conclusion
- Acknowledgments
- Chapter Seven: Molecular Imaging of the Tumor Microenvironment for Precision Medicine and Theranostics
- Abstract
- 1 Introduction
- 2 Imaging and PM/Theranostics of the Physiological Microenvironment
- 3 The ECM and Its Enzymes
- 4 Endothelial Cells and Tumor Vasculature
- 5 Lymphatic Endothelial Cells, Lymphatics, and Interstitial Pressure
- 6 Stromal Components of the TME and Their Role in PM
- 7 Intraoperative Optical Imaging
- 8 Concluding Remarks
- Acknowledgments
- Chapter Eight: Tracking Cellular and Immune Therapies in Cancer
- Abstract
- 1 Introduction
- 2 Molecular Imaging Approaches to Cancer Immunotherapy
- 3 Radionuclide Methods in the Preclinical and Clinical Settings
- 4 MRI Methods in the Preclinical and Clinical Settings
- 5 Opportunities for Improvements and Future Directions
- 6 Conclusions
- Chapter Nine: Developing MR Probes for Molecular Imaging
- Abstract
- 1 General Overview
- 2 T1, T2, T2* Relaxivity-Based Agents
- 3 CEST Probes: Multiple Labeling Frequencies
- 4 19F Probes: Hot-Spot Imaging
- 5 Hyperpolarized Imaging Probes
- Chapter Ten: Clinical Translation of Molecular Imaging Agents Used in PET Studies of Cancer
- Abstract
- 1 Introduction
- 2 FDG—Lessons Learnt
- 3 Stages to Development of a New Radiotracer
- 4 Translating Deregulated Nature-Identical Biochemicals
- 5 Translating Cell Surface and Intracellular Receptors as Predictive Biomarkers
- 6 Translating Probes for Visualization of Life and Death Signals in the Cell
- 7 Translating Tools to Assess Host–Tumor Microenvironment Interactions
- 8 Translating Labeled Drugs and Drug Analogs
- 9 Conclusion
- Acknowledgments
- Index
- No. of pages: 402
- Language: English
- Edition: 1
- Volume: 124
- Published: September 25, 2014
- Imprint: Academic Press
- Hardback ISBN: 9780124116382
- eBook ISBN: 9780124116344
MP
Martin Pomper
Affiliations and expertise
Johns Hopkins University, Baltimore, MD, USAPF
Paul B. Fisher
Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 625 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at Johns Hopkins Medical Center) focusing on imaging and therapy (“theranostics”) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).
Affiliations and expertise
Department of Human and Molecular Genetics, VCU Institute of Molecular Medicine, VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Virginia, USARead Emerging Applications of Molecular Imaging to Oncology on ScienceDirect